Emcure Pharmaceuticals has announced a board meeting scheduled for November 11, 2025, to review and approve the unaudited financial results for the quarter and half-year ended September 30, 2025. The results will be presented in both standalone and consolidated formats. The company has also noted that the trading window for dealing in the company’s securities remains closed until 48 hours after the results are declared, ending November 13, 2025.
Board Meeting Announcement
The Board of Directors of Emcure Pharmaceuticals is set to convene on Tuesday, November 11, 2025. The primary agenda of the meeting is to review and approve the unaudited financial results for the quarter and half-year which concluded on September 30, 2025.
Financial Reporting
During the meeting, the board will consider and approve the unaudited financial results in both standalone and consolidated formats. This will provide a comprehensive view of the company’s financial performance for the reporting period.
Trading Window Closure
Emcure Pharmaceuticals has also announced the continued closure of its trading window for designated persons and their relatives. The window has been closed since October 01, 2025, and will remain closed until 48 hours after the declaration of the unaudited financial results, specifically until November 13, 2025. This is to ensure compliance with insider trading regulations.
Source: BSE
